Please ensure Javascript is enabled for purposes of website accessibility

Why Athersys Stock Jumped Today

By Keith Speights - Updated Dec 21, 2020 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced the enrollment of the first patient in a key clinical study.

What happened

Shares of Athersys (ATHX -1.80%) were jumping 11.2% as of 3:30 p.m. EST on Monday. The solid gain came after the company and the University of Texas Health Science Center at Houston announced the enrollment of the first patient in a phase 2 clinical study evaluating the company's MultiStem cell therapy as a potential early treatment for traumatic injuries.

So what

The enrollment of one patient in a phase 2 study doesn't always cause a biotech stock to jump. But there are some reasons that investors were especially excited about Athersys' announcement.

Scientist looking through a microscope with another scientist in the background

Image source: Getty Images.

The company doesn't have any approved products on the market yet, so the enrollment of the first patient in the phase 2 study for MultiStem represents a major milestone toward changing that status.

The potential market for MultiStem is tremendous if the experimental cell therapy is successful. Trauma is the leading cause of death in the U.S. for people under age 45, according to the Centers for Disease Control and Prevention. It's the No. 3 cause of death for Americans overall and a major cause of severe disability. MultiStem holds the potential to address immune responses that can cause serious complications related to traumatic injuries.

Now what

Athersys is also evaluating MultiStem in other studies, including a phase 2/3 study targeting patients with COVID-19 induced acute respiratory distress syndrome (ARDS) and a late-stage study targeting ischemic stroke. In addition, the company is pursuing partnerships for the cell therapy related to commercialization in Europe and other regions.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Athersys, Inc. Stock Quote
Athersys, Inc.
$0.25 (-1.80%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.